These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 22008272)

  • 1. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in the pharmacotherapeutic management of osteoporosis.
    Close P; Neuprez A; Reginster JY
    Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of postmenopausal osteoporosis.
    Tella SH; Gallagher JC
    J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present and future of the treatment of osteoporosis with monoclonal antibodies].
    Fiter Aresté J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S8-12. PubMed ID: 21924213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets for intervention in the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.